Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;2(3 Suppl):S37-41.

Accomplishments in 2007 in the treatment of metastatic pancreatic cancer

Christophe Louvet  1 , Philip A Philip
Affiliations

Accomplishments in 2007 in the treatment of metastatic pancreatic cancer

Christophe Louvet et al. Gastrointest Cancer Res. 2008 May.

Abstract

Overview of the Disease IncidencePrognosisCurrent Therapy Standards ChemotherapyAccomplishments and Lack of Accomplishments During the Year TherapyBiomarkersBasic ScienceWhat Needs To Be Done (Application of the Accomplishments) Controversies and Disagreements When To Transition to a Phase III Study?What is the Optimum Design for Pilot Studies?Future Directions Comments on ResearchHow To Capture Data From Preclinical Research?Obstacles to ProgressConclusions.

PubMed Disclaimer

References

    1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966. - PubMed
    1. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24:18S. (abstr LBA4004)
    1. Heinemann V, Hincke A, Blöck R, et al. Gemcitabine-based combinations (gem + x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:18S. (abstr 4515)
    1. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:18S. (abstr 4508)
    1. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic adenocarcinoma: SWOG S0205 study. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:18S. (abstr LBA4509)

LinkOut - more resources